Portolan Capital Management’s Transmedics TMDX Stock Holding History

Portolan Capital Management’s Portfolio TMDX Stock Details TMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.06M	Sell	10,688 -86,205	-89%	-$11.2M	0.06%	137
2025 Q4	$11.8M	Buy	96,893 +27,983	+41%	+$3.51M	0.63%	56
2025 Q3	$7.73M	Buy	+68,910	New	+$8.07M	0.42%	70
2025 Q2	–	Sell	-47,536	Closed	-$3.2M	–	141
2025 Q1	$3.2M	Buy	+47,536	New	+$3.27M	0.24%	89
2022 Q2	–	Sell	-379,859	Closed	-$10.2M	–	158
2022 Q1	$10.2M	Buy	+379,859	New	+$6.81M	0.82%	47
2021 Q4	–	Sell	-78,106	Closed	-$2.58M	–	153
2021 Q3	$2.58M	Buy	+78,106	New	+$2.39M	0.19%	110

Other funds holding TMDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Portolan Capital Management's TMDX Position: Q1 2026 in Review

Portolan Capital Management reduced its Transmedics (TMDX) stake by 89% in Q1 2026, selling an estimated $11.2M and leaving 10,688 shares worth $1.06M. The position accounts for 0.06% of the portfolio, ranked #137.

Portolan Capital Management first reported a position in TMDX in Q3 2021 and has held it in 6 quarters since. The position peaked at $11.8M in Q4 2025. 414 funds tracked by Wall St. Rank hold TMDX as of Q1 2026.

Portolan Capital Management held 10,688 shares of Transmedics worth $1.06M as of Q1 2026.
Portolan Capital Management sold 86,205 Transmedics shares in Q1 2026, an estimated $11.2M.
Transmedics made up 0.06% of Portolan Capital Management's portfolio in Q1 2026, its #137 holding.
Portolan Capital Management first reported a position in Transmedics in Q3 2021 and has held it in 6 quarters since.
Portolan Capital Management's Transmedics position peaked at $11.8M in Q4 2025.
414 funds tracked by Wall St. Rank held Transmedics as of Q1 2026.

Based on Portolan Capital Management's 13F filing for Q1 2026, filed 15 May 2026.